136 related articles for article (PubMed ID: 37804738)
21. Predictors of Recurrent Venous Thromboembolism or Arterial Thrombotic Events during and after Anticoagulation for a First Venous Thromboembolism.
Noumegni SR; Tromeur C; Hoffmann C; Mao RL; Moigne EL; Moreuil C; Mansourati V; Nasr B; Gentric JC; Guegan M; Poulhazan E; Bressollette L; Lacut K; Didier R; Couturaud F
Semin Thromb Hemost; 2023 Oct; 49(7):688-701. PubMed ID: 36252603
[TBL] [Abstract][Full Text] [Related]
22. Impact of venous thromboembolism on incidence of arterial thromboembolism - An analysis of German outpatient claims data.
Keller K; Kohring C; Farmakis IT; Valerio L; Barco S; Bätzing J; Akmatov MK; Konstantinides S; Münzel T; Hobohm L; Holstiege J
Thromb Res; 2023 Jun; 226():9-17. PubMed ID: 37079980
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Zhang T; Su D; Li J; Wang Y; Han C; Jiao S; Bai L
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Jun; 18(6):584-8. PubMed ID: 26108774
[TBL] [Abstract][Full Text] [Related]
25. Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
Riedl JM; Posch F; Bezan A; Szkandera J; Smolle MA; Winder T; Rossmann CH; Schaberl-Moser R; Pichler M; Stotz M; Stöger H; Gerger A
BMC Cancer; 2017 Jun; 17(1):415. PubMed ID: 28619086
[TBL] [Abstract][Full Text] [Related]
26. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
27. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
[TBL] [Abstract][Full Text] [Related]
28. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
[TBL] [Abstract][Full Text] [Related]
29. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Sobrero A; Lenz HJ; Eng C; Scheithauer W; Middleton G; Chen W; Esser R; Nippgen J; Burris H
Oncologist; 2021 Feb; 26(2):e261-e269. PubMed ID: 33191588
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
[TBL] [Abstract][Full Text] [Related]
31. Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in
Qin S; Liu T; Xu J; Li Q; Cheng Y; Zhang A; Esser R; Chang H; Li J
Future Oncol; 2023 May; 19(15):1053-1061. PubMed ID: 37017100
[TBL] [Abstract][Full Text] [Related]
32. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
33. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
[TBL] [Abstract][Full Text] [Related]
34. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
36. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
[TBL] [Abstract][Full Text] [Related]
37. A meta analysis of cetuximab plus oxaliplatin based chemotherapy regimen for metastatic colorectal cancer.
Zhu YL; Lou J; Guo JY; Huang Z; Lv SW
Indian J Cancer; 2014 Mar; 51 Suppl 3():e113-6. PubMed ID: 25818736
[TBL] [Abstract][Full Text] [Related]
38. Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Maharaj S; Chang S; Seegobin K; Serrano-Santiago I; Zuberi L
Expert Rev Anticancer Ther; 2017 Jul; 17(7):585-591. PubMed ID: 28508703
[TBL] [Abstract][Full Text] [Related]
39. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Lipsyc-Sharf M; Ou FS; Yurgelun MB; Rubinson DA; Schrag D; Dakhil SR; Stella PJ; Weckstein DJ; Wender DB; Faggen M; Zemla TJ; Heying EN; Schuetz SR; Noble S; Meyerhardt JA; Bekaii-Saab T; Fuchs CS; Ng K
Oncologist; 2022 Apr; 27(4):292-298. PubMed ID: 35380713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
